Figures computed from official regulatory filings — .
Analysttarget 500 USD (+4504405%) · consensus 4/5 · 1 buy · 0 hold · 0 sell
Ownershipinsiders 0% · institutions 0% · short 3.1% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for Panbela Therapeutics, Inc. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The company's lead product candidates are Ivospemin (SBP-101), a proprietary polyamine analogue, which has completed Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma; Flynpovi, a combination of eflornithine (CPP-1X) and sulindac which is in Phase III clinical trials; and Eflornithine, an enzyme-activated irreversible inhibitor of the enzyme ornithine decarboxylase, currently under Phase I/II trial. It has a research agreement with the Johns Hopkins University School of Medicine for the development of ivospemin. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.
Market information source · Oct 5, 2026
Periods recorded in the consulted sources. These do not certify the legal dates of name changes.
SEC company identity · Oct 5, 2026
Open-market timeline · full history
31 buys9 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details |
|---|---|---|---|---|
| Nant Capital, LLC | BuyD (derivative) | n/a (Converted to USD in the nightly refresh) | First in 12mo |
| SEC |
| Horvath Susantrack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Simpson Jennifer K.track record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| GOLDMAN SACHS & COtrack record | Sell | $51.7K | SEC |
| Jacob Jeffrey E. | Gift | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Jacob Jeffrey E. | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Donovan Daniel | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Horvath Susantrack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Fratamico Arthur | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Schemel Donald Robert | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| MATHIESEN JEFFREY Strack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Simpson Jennifer K.track record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Cullen Michael T.track record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Horvath Susantrack record | BuyD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | First in 12mo | SEC |
| Simpson Jennifer K.track record | BuyD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | First in 12mo | SEC |
| Simpson Jennifer K.track record | Buy | n/a (No price was disclosed in the filing) | conv 97First in 12mo | SEC |
| Horvath Susantrack record | Buy | n/a (No price was disclosed in the filing) | conv 79First in 12mo | SEC |
| Schemel Donald Robert | BuyD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | ClusterFirst in 12mo | SEC |
| Jacob Jeffrey E. | BuyD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | ClusterFirst in 12mo | SEC |
| Jacob Jeffrey E. | Buy | n/a (No price was disclosed in the filing) | conv 58ClusterFirst in 12mo | SEC |
| Cullen Michael T.track record | Buy | n/a (No price was disclosed in the filing) | conv 89ClusterFirst in 12mo | SEC |
| Cullen Michael T.track record | BuyD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | ClusterFirst in 12mo | SEC |
| Schemel Donald Robert | Buy | n/a (No price was disclosed in the filing) | conv 83ClusterFirst in 12mo | SEC |
| Horvath Susantrack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Simpson Jennifer K.track record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |